Johnson & Johnson Announces Positive Topline Results from Phase III MARIPOSA Study of Rybrevant (amivantamab) Plus Lazertinib vs. Osimertinib in First-Line EGFR-Mutated NSCLC

On September 28, Johnson & Johnson announced that the Phase III MARIPOSA study evaluating Rybrevant (amivantamab), an EGFR/c-MET bispecific antibody, in combination with the third-generation EGFR inhibitor Lazertinib versus osimertinib for the treatment of patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), achieved positive topline data.

The results showed that the MARIPOSA study met its primary endpoint, with patients in the Rybrevant+Lazertinib treatment group experiencing a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to the osimertinib treatment group. In terms of safety, the safety profile of the Rybrevant+Lazertinib combination was consistent with previously reported data.

Moreover, the interim overall survival (OS) analysis showed that, compared with the osimertinib treatment group, the Rybrevant+Lazertinib treatment group demonstrated a trend toward OS benefit.

It is worth mentioning that Johnson & Johnson also announced this month that the Phase III MARIPOSA-2 study of Rybrevant in combination with Lazertinib and chemotherapy for the treatment of osimertinib resistance met its primary endpoint of PFS. MARIPOSA-2 has also become the first Phase III study to bring a clinically meaningful improvement in PFS for post-osimertinib treatment ().

Copyright © 2023 PHARMCUBE. All Rights Reserved.

Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article; if you need to reprint, please leave a message or send a notification to the WeChat Official Account backend, and include the name and ID of the official account.

Disclaimer: The information in this WeChat article is for general reference only and should not be directly used as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.